Novo Nordisk’s widely popular GLP-1 analog Victoza made headlines at the beginning of the year when celebrity chef Paula Deen became a spokesperson…
Category: Injectable Medication
The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents...
"Paula Deen is not the diabetes poster child," said Ambre Morely, associate director of product communications at Novo Nordisk. "She's an everyday person with type 2 diabetes...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone)...
The newly approved type 2 diabetes drug Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by prescription in U.S. pharmacies.
Bydureon is the first and only once-weekly treatment for type 2 diabetes. It was approved by the US FDA ...
Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatment for type 2 diabetes. The drug which received EU approval in June was turned down by the FDA twice during 2010, requesting further testing be conducted...
Paula Deen has been privately suffering from type 2 diabetes for three years. Now she’s gone public with both her diabetes and her treatment with Victoza...
After days of rumors regarding Paula Deen's diabetes diagnosis, the woman dubbed the Queen of Southern Cuisine has announced that she and her sons have partnered up with Novo Nordisk to launch Diabetes in a New Light™, a national initiative to help adults find simple ways...
Sanofi announced positive results from the Gel Duo 1 study of it's investigational GLP-1 agonist, Lyxumia (lixisenatide) in the treatment of type 2 diabetes patients. The results show that patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin - significantly reduced their HbA1c levels when...
Results showed a reduction in HbA1c of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide. While albiglutide did demonstrate a statistically significant reduction in HbA1c from baseline (p<0.001), it did not meet the pre-specified primary endpoint of non-inferiority to liraglutide...